http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H03151323-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69c0ba7037f9003fddd25919eee4a97a
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-70
filingDate 1989-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3473604ef1626cb0452fe612626e1af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7634deaf866dcc4de6ddfa843b171d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adeeceddac79ecaa1ff0a276485532de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_476d4101ffb92d1ab2995186988ae731
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e690c44ee7d32653d5405c8872a4a6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e17d516c085579b10f206fe5808f3c3d
publicationDate 1991-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H03151323-A
titleOfInvention Substituted phenylalkanoylamine derivative and use thereof
abstract PURPOSE: To obtain a cerebral circulation, cerebral metabolism and anamnesis improving agent having excellent anti-low oxygen action with high safety containing a substituted phenylalkanoylamine derivative. n CONSTITUTION: A compound expressed by the formula (A is 1,3-thiazolidin-3-yl, 1,2,3,6-tetrahydropyridin-1-yl, thiomorpholin-4-yl or 3-pyrrolin-1-yl; R is lower alkyl-substituted amino, pyrrolidin-1-yl, piperidino or guanidino; n is 2-6) or salt of said compound, e.g. 3-{4-[4-(N,N-dimethylamino)phenyl]butanoyl}-1,3- thiazolidine, is contained in the aimed agent as active ingredient. Administration dose of said agent is suitably in a range of 1-2000mg/day, preferably 10-200mg/ day at 1-3 times per day in a case of oral administration. n COPYRIGHT: (C)1991,JPO&Japio
priorityDate 1989-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID977
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234948707
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456144919
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413116774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457475723
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19772147

Total number of triples: 29.